Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Benefits of pharmacotherapy for preventing hip fracture

Patrick Quail
CMAJ April 19, 2016 188 (7) 531; DOI: https://doi.org/10.1503/cmaj.1150090
Patrick Quail
University of Calgary, Calgary, Alta.
MB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Although falls and fractures are common in nursing homes, the guideline on preventing fracture in long-term care in CMAJ emphasizes therapies of unproven benefit and small effect size.1 The authors recognize that the evidence for their recommendations for pharmacotherapy in preventing fractures in long term care is weak; however, even with stronger evidence, the effect size remains very small and possibly not significant, at 2.5% for hip fracture prevention over two years.

The studies used to develop this guideline typically involved community-dwelling patients nearly 20 years younger than the average patient in a nursing home. In our homes in Calgary (Intercare Corporate Group Inc.), the average annual incidence of hip fracture over the past 9 years has been 7.2/100 000 resident days, or approximately 18 hip fractures a year across 700 beds.

For a medium-sized home (200 residents), we could therefore expect 5 hip fractures a year, or 10 hip fractures over 2 years. If, as the authors suggest, we could reduce the fractures by 25 for every 1000 residents treated (number needed to treat = 40) over 2 years, we would need to treat every patient (assuming 100% residents are at high risk and that all survive 2 years after admission) for 2 years to prevent 5 hip fractures in a 200-bed home. However, the median length of stay is 1.9 years in Calgary homes, so 50% of our patients would not survive to see a benefit at 2 years. This, in crude terms, would therefore reduce the number of “prevented hip fractures” by only 2.5.

Such a recommendation is not an attractive or realistic proposition to most patients or providers, especially without any reference to numbers needed to harm. To further complicate matters, we are poor at estimating prognosis in the nursing home setting — only really understanding that a third of our patients will die in any given year. Selecting patients who are likely to survive one year is challenging in those with end-stage chronic disease such as dementia. The authors arbitrarily place a one-year decision point in Figure 1 without any rationale to support it. Also, the broad application of this guideline, as illustrated in Figure 1, makes no reference to the wishes of patients and therefore the appropriateness of the interventions.

More attention perhaps should have been given to targeted high-risk populations in nursing homes who might be expected to experience realistic benefits. We need a better understanding of which patients to treat and what the actual effect size is in the nursing home.

I look forward to the results of future research using complex, frail nursing home patients with multiple comorbidities. It goes without saying that we would dearly love to reduce our rates of hip fracture morbidity and mortality.

Reference

  1. ↵
    1. Papaioannou A,
    2. Santesso N,
    3. Morin SN,
    4. et al
    . Recommendations for preventing fracture in long-term care. CMAJ 2015;187:1135–44.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (7)
CMAJ
Vol. 188, Issue 7
19 Apr 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Benefits of pharmacotherapy for preventing hip fracture
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Benefits of pharmacotherapy for preventing hip fracture
Patrick Quail
CMAJ Apr 2016, 188 (7) 531; DOI: 10.1503/cmaj.1150090

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Benefits of pharmacotherapy for preventing hip fracture
Patrick Quail
CMAJ Apr 2016, 188 (7) 531; DOI: 10.1503/cmaj.1150090
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Reference
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire